FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022008229> ?p ?o ?g. }

• W2022008229 endingPage "389" @default.
• W2022008229 startingPage "383" @default.
• W2022008229 abstract "Background Current treatment guidelines define inhaled corticosteroids such as fluticasone propionate (FP) as the cornerstone of anti-inflammatory therapy for asthma. Objective The objective was to evaluate the efficacy and safety of adding salmeterol therapy to patients who remain symptomatic while receiving FP as compared with increasing the dose of FP. Methods In a multicenter, double-blind study conducted over 24-weeks, 437 patients aged 12 years and older and receiving FP 88 μg twice daily for 2 to 4 weeks were randomly assigned to receive either salmeterol (42 μg twice daily) or FP 220 μg twice daily. The primary efficacy endpoint was morning peak expiratory flow. Secondary measures included FEV1, symptom scores, nighttime awakenings, and supplemental albuterol use. Safety was assessed by reported adverse events and asthma exacerbations. Results The addition of salmeterol resulted in significantly greater improvements in lung function and symptom control as compared with increasing the dose of FP. Over weeks 1 to 24, morning peak expiratory flow was increased by 47 L/min from baseline with salmeterol treatment as compared with 24 L/min with FP 220 μg twice daily (P < .001) while the percent of symptom-free days increased from baseline by 26% of days as compared with 10% of days (P < .001). The adverse event profiles were similar between groups and fewer exacerbations were reported with salmeterol treatment. Conclusions The addition of salmeterol therapy to patients who remain symptomatic while using a low dose of FP was clinically and statistically superior to increasing the dose of FP. Current treatment guidelines define inhaled corticosteroids such as fluticasone propionate (FP) as the cornerstone of anti-inflammatory therapy for asthma. The objective was to evaluate the efficacy and safety of adding salmeterol therapy to patients who remain symptomatic while receiving FP as compared with increasing the dose of FP. In a multicenter, double-blind study conducted over 24-weeks, 437 patients aged 12 years and older and receiving FP 88 μg twice daily for 2 to 4 weeks were randomly assigned to receive either salmeterol (42 μg twice daily) or FP 220 μg twice daily. The primary efficacy endpoint was morning peak expiratory flow. Secondary measures included FEV1, symptom scores, nighttime awakenings, and supplemental albuterol use. Safety was assessed by reported adverse events and asthma exacerbations. The addition of salmeterol resulted in significantly greater improvements in lung function and symptom control as compared with increasing the dose of FP. Over weeks 1 to 24, morning peak expiratory flow was increased by 47 L/min from baseline with salmeterol treatment as compared with 24 L/min with FP 220 μg twice daily (P < .001) while the percent of symptom-free days increased from baseline by 26% of days as compared with 10% of days (P < .001). The adverse event profiles were similar between groups and fewer exacerbations were reported with salmeterol treatment. The addition of salmeterol therapy to patients who remain symptomatic while using a low dose of FP was clinically and statistically superior to increasing the dose of FP." @default.
• W2022008229 created "2016-06-24" @default.
• W2022008229 creator A5011317805 @default.
• W2022008229 creator A5036000357 @default.
• W2022008229 creator A5044198485 @default.
• W2022008229 creator A5056947570 @default.
• W2022008229 creator A5076439834 @default.
• W2022008229 creator A5078664755 @default.
• W2022008229 date "1999-04-01" @default.
• W2022008229 modified "2023-10-18" @default.
• W2022008229 title "The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma" @default.
• W2022008229 cites W1977466243 @default.
• W2022008229 cites W1987062528 @default.
• W2022008229 cites W2010822535 @default.
• W2022008229 cites W2071302230 @default.
• W2022008229 cites W2077047005 @default.
• W2022008229 cites W2098633046 @default.
• W2022008229 cites W2110694086 @default.
• W2022008229 cites W2331287401 @default.
• W2022008229 cites W3140217998 @default.
• W2022008229 cites W4249200669 @default.
• W2022008229 doi "https://doi.org/10.1016/s1081-1206(10)63288-7" @default.
• W2022008229 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10227337" @default.
• W2022008229 hasPublicationYear "1999" @default.
• W2022008229 type Work @default.
• W2022008229 sameAs 2022008229 @default.
• W2022008229 citedByCount "146" @default.
• W2022008229 countsByYear W20220082292013 @default.
• W2022008229 countsByYear W20220082292014 @default.
• W2022008229 countsByYear W20220082292015 @default.
• W2022008229 countsByYear W20220082292016 @default.
• W2022008229 countsByYear W20220082292018 @default.
• W2022008229 countsByYear W20220082292020 @default.
• W2022008229 countsByYear W20220082292022 @default.
• W2022008229 crossrefType "journal-article" @default.
• W2022008229 hasAuthorship W2022008229A5011317805 @default.
• W2022008229 hasAuthorship W2022008229A5036000357 @default.
• W2022008229 hasAuthorship W2022008229A5044198485 @default.
• W2022008229 hasAuthorship W2022008229A5056947570 @default.
• W2022008229 hasAuthorship W2022008229A5076439834 @default.
• W2022008229 hasAuthorship W2022008229A5078664755 @default.
• W2022008229 hasConcept C126322002 @default.
• W2022008229 hasConcept C168563851 @default.
• W2022008229 hasConcept C19720800 @default.
• W2022008229 hasConcept C197934379 @default.
• W2022008229 hasConcept C203092338 @default.
• W2022008229 hasConcept C2776042228 @default.
• W2022008229 hasConcept C2776719499 @default.
• W2022008229 hasConcept C2776804153 @default.
• W2022008229 hasConcept C2779028295 @default.
• W2022008229 hasConcept C2781018748 @default.
• W2022008229 hasConcept C2781212218 @default.
• W2022008229 hasConcept C42219234 @default.
• W2022008229 hasConcept C71924100 @default.
• W2022008229 hasConceptScore W2022008229C126322002 @default.
• W2022008229 hasConceptScore W2022008229C168563851 @default.
• W2022008229 hasConceptScore W2022008229C19720800 @default.
• W2022008229 hasConceptScore W2022008229C197934379 @default.
• W2022008229 hasConceptScore W2022008229C203092338 @default.
• W2022008229 hasConceptScore W2022008229C2776042228 @default.
• W2022008229 hasConceptScore W2022008229C2776719499 @default.
• W2022008229 hasConceptScore W2022008229C2776804153 @default.
• W2022008229 hasConceptScore W2022008229C2779028295 @default.
• W2022008229 hasConceptScore W2022008229C2781018748 @default.
• W2022008229 hasConceptScore W2022008229C2781212218 @default.
• W2022008229 hasConceptScore W2022008229C42219234 @default.
• W2022008229 hasConceptScore W2022008229C71924100 @default.
• W2022008229 hasIssue "4" @default.
• W2022008229 hasLocation W20220082291 @default.
• W2022008229 hasLocation W20220082292 @default.
• W2022008229 hasOpenAccess W2022008229 @default.
• W2022008229 hasPrimaryLocation W20220082291 @default.
• W2022008229 hasRelatedWork W174026561 @default.
• W2022008229 hasRelatedWork W2014561368 @default.
• W2022008229 hasRelatedWork W2038694240 @default.
• W2022008229 hasRelatedWork W2045449026 @default.
• W2022008229 hasRelatedWork W2098219249 @default.
• W2022008229 hasRelatedWork W2293620483 @default.
• W2022008229 hasRelatedWork W2940923869 @default.
• W2022008229 hasRelatedWork W2984327395 @default.
• W2022008229 hasRelatedWork W3030704863 @default.
• W2022008229 hasRelatedWork W4249328199 @default.
• W2022008229 hasVolume "82" @default.
• W2022008229 isParatext "false" @default.
• W2022008229 isRetracted "false" @default.
• W2022008229 magId "2022008229" @default.
• W2022008229 workType "article" @default.